TACSTD2 and posterior cortical atrophy: In this situation, sacituzumab govitecan (IMMU-132), an antibody–drug conjugate consisting of an anti-Trop2 antibody linked to the active topoisomerase inhibitor, represents a cytotoxic drug targeting DNA replication that has shown efficacy against malignancies other than PCa [115].